CombiMatrix Corporation (CombiMatrix) has appointed former US Food and Drug Administration (FDA) deputy commissioner Scott Gottlieb to the company as board of director. During his tenure at the FDA, Gottlieb was the highest-ranking official below the FDA Commissioner. Gottlieb is presently a resident fellow at the American Enterprise Institute. Gottlieb also practices medicine as an attending physician at Stamford Hospital in Connecticut.
Scott Gottlieb served as FDA Deputy Commissioner for Medical and Scientific Affairs for the period 2005-2007, and prior to that, from 2003-2004, as senior advisor for medical technology to the FDA Commissioner and as the FDA’s director of medical policy development. He left the FDA in the spring of 2004 to work on implementation of the new medicare drug benefit as a senior adviser to the administrator of medicare and medicaid services, where he supported the agency’s policy work on quality improvement and coverage and payment decision-making, particularly related to new medical technologies.
Gottlieb has received numerous awards and is the author of over 300 articles that have appeared in leading medical journals and publications including The Wall Street Journal and The New York Times. Additionally, he has held editorial roles at the British Medical Journal and the Journal of the American Medical Association. Gottlieb also regularly appears as an expert commentator on CNBC, Fox News, Bloomberg Television, and other business and news channels.
Gottlieb completed his residency in internal medicine at the Mount Sinai Hospital in New York City and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University in Connecticut.
“Dr. Gottlieb is a leading expert in healthcare policy whose work focuses on providing insights into the economic, regulatory, and technological forces driving the transformation of medicine. His experience and insight will be useful as we continue the development and commercialization of new diagnostic array-based genetic tests, a market in which we provide by far the broadest portfolio of tests,” said Amit Kumar, president and chief executive officer of CombiMatrix.
“CombiMatrix’s molecular diagnostics technology is at the forefront of the rapidly advancing field of personalized medicine, which is making notable contributions to improving the treatment of cancer and other diseases,” stated Gottlieb. “I look forward to working with the company as it makes additional progress in developing tools that will improve the public health.”